Genetic Technologies Ltd (GENE) Fundamental Analysis & Valuation

NASDAQ:GENE • US37185R4065

Current stock price

0.765 USD
-0.02 (-1.92%)
At close:
0.75 USD
-0.02 (-1.96%)
After Hours:

This GENE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. GENE Profitability Analysis

1.1 Basic Checks

  • In the past year GENE has reported negative net income.
  • In the past year GENE has reported a negative cash flow from operations.
  • GENE had negative earnings in each of the past 5 years.
  • GENE had a negative operating cash flow in each of the past 5 years.
GENE Yearly Net Income VS EBIT VS OCF VS FCFGENE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

  • The Return On Assets of GENE (-194.25%) is worse than 98.21% of its industry peers.
  • GENE has a Return On Equity of -656.53%. This is amonst the worse of the industry: GENE underperforms 92.86% of its industry peers.
Industry RankSector Rank
ROA -194.25%
ROE -656.53%
ROIC N/A
ROA(3y)-102.54%
ROA(5y)-75.74%
ROE(3y)-268.4%
ROE(5y)-176.61%
ROIC(3y)N/A
ROIC(5y)N/A
GENE Yearly ROA, ROE, ROICGENE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

  • GENE has a Gross Margin (50.94%) which is comparable to the rest of the industry.
  • The Profit Margin and Operating Margin are not available for GENE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 50.94%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GENE Yearly Profit, Operating, Gross MarginsGENE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. GENE Health Analysis

2.1 Basic Checks

  • GENE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, GENE has more shares outstanding
  • The number of shares outstanding for GENE has been reduced compared to 5 years ago.
  • The debt/assets ratio for GENE is higher compared to a year ago.
GENE Yearly Shares OutstandingGENE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
GENE Yearly Total Debt VS Total AssetsGENE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

  • GENE has an Altman-Z score of -40.90. This is a bad value and indicates that GENE is not financially healthy and even has some risk of bankruptcy.
  • GENE has a worse Altman-Z score (-40.90) than 96.43% of its industry peers.
  • GENE has a Debt/Equity ratio of 0.36. This is a healthy value indicating a solid balance between debt and equity.
  • With a Debt to Equity ratio value of 0.36, GENE perfoms like the industry average, outperforming 46.43% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF N/A
Altman-Z -40.9
ROIC/WACCN/A
WACC10.02%
GENE Yearly LT Debt VS Equity VS FCFGENE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

2.3 Liquidity

  • GENE has a Current Ratio of 0.88. This is a bad value and indicates that GENE is not financially healthy enough and could expect problems in meeting its short term obligations.
  • GENE's Current ratio of 0.88 is on the low side compared to the rest of the industry. GENE is outperformed by 91.07% of its industry peers.
  • A Quick Ratio of 0.83 indicates that GENE may have some problems paying its short term obligations.
  • GENE has a Quick ratio of 0.83. This is amonst the worse of the industry: GENE underperforms 87.50% of its industry peers.
Industry RankSector Rank
Current Ratio 0.88
Quick Ratio 0.83
GENE Yearly Current Assets VS Current LiabilitesGENE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. GENE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 19.74% over the past year.
  • Looking at the last year, GENE shows a very negative growth in Revenue. The Revenue has decreased by -11.76% in the last year.
  • Measured over the past years, GENE shows a very strong growth in Revenue. The Revenue has been growing by 213.18% on average per year.
EPS 1Y (TTM)19.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.06%
Revenue 1Y (TTM)-11.76%
Revenue growth 3Y299.13%
Revenue growth 5Y213.18%
Sales Q2Q%-18.23%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GENE Yearly Revenue VS EstimatesGENE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

Find the best growth stocksShow best growing peers

0

4. GENE Valuation Analysis

4.1 Price/Earnings Ratio

  • GENE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GENE Price Earnings VS Forward Price EarningsGENE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GENE Per share dataGENE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GENE Dividend Analysis

5.1 Amount

  • No dividends for GENE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

GENE Fundamentals: All Metrics, Ratios and Statistics

Genetic Technologies Ltd

NASDAQ:GENE (10/16/2024, 9:36:40 PM)

After market: 0.75 -0.02 (-1.96%)

0.765

-0.02 (-1.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-29
Earnings (Next)N/A
Inst Owners2.68%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.58M
Revenue(TTM)7.66M
Net Income(TTM)-12.02M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.51
P/FCF N/A
P/OCF N/A
P/B 2.12
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.74
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.91
FCFYN/A
OCF(TTM)-1.91
OCFYN/A
SpS1.51
BVpS0.36
TBVpS-0.06
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -194.25%
ROE -656.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 50.94%
FCFM N/A
ROA(3y)-102.54%
ROA(5y)-75.74%
ROE(3y)-268.4%
ROE(5y)-176.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover1.24
Health
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 0.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.88
Quick Ratio 0.83
Altman-Z -40.9
F-Score4
WACC10.02%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)0.69%
Cap/Sales(5y)201.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.06%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-11.76%
Revenue growth 3Y299.13%
Revenue growth 5Y213.18%
Sales Q2Q%-18.23%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y0.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.45%
OCF growth 3YN/A
OCF growth 5YN/A

Genetic Technologies Ltd / GENE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of Genetic Technologies Ltd (GENE) stock?

ChartMill assigns a fundamental rating of 1 / 10 to GENE.


What is the valuation status for GENE stock?

ChartMill assigns a valuation rating of 0 / 10 to Genetic Technologies Ltd (GENE). This can be considered as Overvalued.


How profitable is Genetic Technologies Ltd (GENE) stock?

Genetic Technologies Ltd (GENE) has a profitability rating of 0 / 10.


How financially healthy is Genetic Technologies Ltd?

The financial health rating of Genetic Technologies Ltd (GENE) is 1 / 10.